Literature DB >> 16148496

MRSA pneumonia: better outcome through continuous infusion of vancomycin?

Stijn Blot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16148496     DOI： 10.1097/01.ccm.0000178288.70057.47

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  8 in total

1.  Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.

Authors:  D D Yeh; M E Kutcher; K Lunghi
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-15       Impact factor: 3.693

2.  Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

3.  Gram-positive cocci infections in intensive care: guide to antibacterial selection.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Maria-Pilar Gracia-Arnillas
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy.

Authors:  J Gómez; E García-Vázquez; R Baños; M Canteras; J Ruiz; V Baños; J A Herrero; M Valdés
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

5.  Pulmonary versus systemic delivery of antibiotics: comparison of vancomycin dispositions in the isolated rat lung.

Authors:  María José de Jesús Valle; Francisco González López; Alfonso Domínguez-Gil Hurlé; Amparo Sánchez Navarro
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

6.  Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens.

Authors:  Andres Beiras-Fernandez; Ferdinand Vogt; Ralf Sodian; Florian Weis
Journal:  Infect Drug Resist       Date:  2010-08-30       Impact factor: 4.003

7.  Daptomycin for the treatment of major gram-positive infections after cardiac surgery.

Authors:  A Kornberger; B Luchting; F Kur; M Weis; F Weis; U A Stock; A Beiras-Fernandez
Journal:  J Cardiothorac Surg       Date:  2016-08-04       Impact factor: 1.637

8.  Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.

Authors:  Stijn Blot; Despoina Koulenti; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Crit Care       Date:  2014-05-15       Impact factor: 9.097
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.